The significance of these findings was not confined to breast cancer patients, since overall survival (OS) in HER2-positive gastric cancer patients was also significantly lower if patients expressed high combined mean mRNA levels of JAM-A, HER2 and FOXA1 (Supplemental Figure S6A). The gene discussed is ERBB2; the disease is breast carcinoma.